A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Mar 16, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on understanding various plasma cell disorders (PCDs), which include conditions like multiple myeloma and amyloidosis, among others. The goal is to create a group of patients with these disorders who are being treated at Peking University First Hospital. By collecting information about their health, treatments, and responses to those treatments, researchers hope to learn more about these conditions. Additionally, they will gather samples of blood, bone marrow, and urine to help with future research.

To participate, patients must have a confirmed diagnosis of one of the PCDs and be hospitalized at the hospital. They will need to agree to take part in the study by signing an informed consent form. While participants will be closely monitored and have their health data collected, it’s important to note that those with serious other health issues that could be life-threatening may not be eligible for this trial. This study aims to shed light on the characteristics of these disorders and how they develop, which could lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)
• • 2. Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).
• • 3. Patients are included into this cohort after signing the ICFs.
• Exclusion Criteria:
• • Significant comorbidity may be life-threatening.